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Objective: There have been significant improvements in the design and manufacturing of
deep brain stimulation (DBS) systems, but no study has considered the impact of modern
systems on complications. We sought to compare the relative occurrence of reoperations
after de novo implantation of modern and traditional DBS systems in patients with
Parkinson’s disease (PD) or essential tremor (ET) in the United States.
Design: Retrospective, contemporaneous cohort study.
Setting: Multicenter data from the United States Centers for Medicare and Medicaid
Services administrative claims database between 2016 and 2018.
Participants: This population-based sample consisted of 5,998 patients implanted with
a DBS system, of which 3,869 patients had a de novo implant and primary diagnosis of
PD or ET. Follow-up of 3 months was available for 3,810 patients, 12 months for 3,561
patients, and 24 months for 1,812 patients.
Intervention: Implantation of a modern directional (MD) or traditional omnidirectional
(TO) DBS system.
Primary and Secondary Outcome Measures: We hypothesized that MD systems
would impact complication rates. Reoperation rate was the primary outcome. Associated
diagnoses, patient characteristics, and implanting center details served as covariates.
Kaplan–Meier analysis was performed to compare rates of event-free survival and
regression models were used to determine covariate influences.
Results: Patients implanted with modern systems were 36% less likely to require
reoperation, largely due to differences in acute reoperations and intracranial lead
reoperations. Risk reduction persisted while accounting for practice differences and
implanting center experience. Risk reduction was more pronounced in patients with PD.
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Conclusions: In the first multicenter analysis of device-related complications including
modern DBS systems, we found that modern systems are associated with lower
reoperation rates. This risk profile should be carefully considered during device selection
for patients undergoing DBS for PD or ET. Prospective studies are needed to further
investigate underlying causes.
Keywords: deep brain stimulation, Parkinson’s disease, essential tremor, Medicare, big data & analytics,
neurosurgery, complications, surgical risk

STRENGTHS AND LIMITATIONS OF THIS
STUDY

reoperation after de novo implantation of modern directional
(MD) and TO DBS systems in patients with PD and ET in the
United States.

• Strict inclusion and exclusion criteria provide a
reliable comparison between two different deep brain
stimulator systems.
• Use of the Centers for Medicare and Medicaid Services (CMS)
administrative claims database provides a large volume of data
for analysis.
• The CMS database provides objective data from multiple
centers within the United States.
• Analysis is limited to the information within the CMS database
because more in-depth clinical data was not available to
provide a more complete picture of each clinical scenario.
• The retrospective nature of the study prevents the ability to
control all confounding variables.

MATERIALS AND METHODS
We conducted an observational, non-randomized, retrospective,
contemporaneous cohort study of Medicare patients undergoing
DBS implantation in the United States. Data from the Centers
for Medicare and Medicaid Services (CMS) administrative claims
database were analyzed to identify DBS implantations performed
in patients with PD and ET. Revision and removal procedures
performed within 2 years of follow-up were compared between
an MD and TO DBS systems.

Data Sources
Eligibility, baseline characteristics, and outcomes were derived
from CMS longitudinal administrative claims files between
2013 and 2019. Patients who underwent implantation between
October 6, 2016 and December 31, 2018 were included. This was
a unique period during which the Abbott InfinityTM system was
the only commercially available MD system in the United States.
Cross-referencing between the Abbott Patient Device Tracking
(PDT) database and the CMS database allowed classification of
the subgroups of interest. The use of CMS data and linkage to
the PDT database were approved through a data use agreement
(RSCH-2019-53524) with CMS. This agreement was established
with Abbott, who provided funding for this study.

INTRODUCTION
Deep brain stimulation (DBS) is a highly effective treatment for
movement disorders like essential tremor (ET) and Parkinson’s
disease (PD). While multiple randomized controlled trials have
demonstrated the superiority of DBS over best medical therapy
in PD, it is associated with approximately twice as many
complications (1). This risk–benefit ratio plays a significant role
in willingness to consider DBS implantation and may contribute
to its current underutilization (2).
Although numerous studies have described DBS
complications, reporting has been inconsistent—with rates
ranging between 0 and 20% and with exact values not being
reported at times (3). Furthermore, studies have been limited
to traditional omnidirectional (TO) DBS systems. No study
has considered the impact of modern DBS systems, which
include a number of innovations. While much attention has
been paid to segmented lead design allowing for stimulation
field shaping (4, 5), modern systems also differ in design and
construction of its other components. We, therefore, sought to
compare the relative occurrence of complications necessitating

Ethics Approval
The research protocol was approved by Western Institutional
Review Board (IRB) with a waiver of informed consent and a
HIPAA waiver.

Patient and Public Involvement
As this was retrospective cohort study performed on anonymized
data, it was not possible to involve patients in the design, conduct,
or reporting of this study.

Abbreviations: CCW, Chronic Conditions Warehouse; CMS, Centers for
Medicare and Medicaid Services; CPT, Current Procedural Terminology;
DBS, deep brain stimulation; ET, essential tremor; HR, hazard ratio; ICD,
International Classification of Diseases; IPG, implantable pulse generator; MBSF,
Master Beneficiary Summary File; MER, microelectrode recording; MD, modern
directional; NPI, national provider identifier; PD, Parkinson’s disease; PDT,
Patient Device Tracking; TO, traditional omnidirectional; VRDC, Virtual Research
Data Center.

Frontiers in Neurology | www.frontiersin.org

Medicare Claims Files
The CMS database consists of administrative claims for
healthcare encounters including inpatient hospital, outpatient
hospital, and physician claims. Relevant International
Classification of Diseases procedure (ICD-10-PCS) and
diagnosis (ICD-10-CM) codes, and Current Procedural
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TABLE 1 | List of procedure codes defining reoperations and diagnosis codes used for classifying reason for complication.
Lead Implant procedure codes
For inclusion
ICD-10-PCS
CPT

00H00MZ, 00H03MZ, 00H04MZ
61863, 61864 (without MER)
61867, 61868 (with MER)

IPG Implant procedure codes
For inclusion
ICD-10-PCS
CPT

0JH60BZ, 0JH60DZ, 0JH60EZ, 0JH63BZ, 0JH63DZ, 0JH63EZ, 0JH70BZ, 0JH70DZ, 0JH70EZ,
0JH73BZ, 0JH73DZ, 0JH73EZ, 0JH80BZ, 0JH80DZ, 0JH80EZ, 0JH83BZ, 0JH83DZ, 0JH83EZ
61885, 61886

Lead/IPG Revision/Removal procedure codes
For exclusion
ICD-10-PCS
CPT

00P00MZ, 00P03MZ, 00P04MZ, 00P0XMZ 00W00MZ, 00W03MZ (lead)
0JPT0MZ, 0JPT3MZ, 0JWT0MZ, 0JWT3MZ (IPG)
61880 (lead), 61888 (IPG)

DBS Analysis and Programming procedure codes
For exclusion
CPT

95978, 95979, 95983, 95984, 95970

Diagnosis codes (ICD-10-CM)
For inclusion
Parkinson’s disease
Essential tremor

G20, G21.11, G21.19, G21.2, G21.3, G21.8, G21.9, G23.1, G31.83, G31.85
G25.0, G25.1, G25.2

Cause of complications (ICD-10-CM)
When present on primary diagnosis or other diagnosis code associated with one of the procedures listed above
Infection
Includes infection of lead, IPG, or other, when associated with a
revision or removal procedure

T8140XA, T8140XD, T8141XA, T8141XS, T8142XA, T8142XD, T8143XA, T8149XA, T814XXA,
T814XXD, T814XXS, T8460XA, T85731A, T85731D, T85734A, T85738A, T85738S, T8579XA,
T8579XD, T8579XS, A414, A419, A4901, B451, B9562, B965, B999, G060, G08, L03313, L089,
S0100XA, S0102XA, T8130XA, T8130XD, T8131XA, T8131XD, T8131XS, T8132XA, T8132XD,
T85732A, T85733D

Hardware malfunction
Includes hardware break, displacement/migration, various
mechanical complications, adjustment, and erosion

T82110A, T85110A, T85110D, T85110S, T85111A, T85113A, T85113D, T85113S, T85118A,
T85118D, T85118S, T85120A, T85120D, T85120S, T85121A, T85123A, T85128A, T85190A,
T85190D, T85190S, T85193A, T85193D, T85193S, T85199A, T85199D, T85615A, T85618A,
T85618D, T85625A, T85628A, T85695A, T85695D, T85695S, T85698A, T85698D, T85890A,
T85890D, T85890S, T82897A, T85191A, T85898A, T8589XA, T8589XD, T859XXA, Z4542, Z4549,
Z4589, Z459, Z462

Other/Unidentified

Any procedure not having one of the above diagnosis codes

(IPG) components of the DBS system. It also contains patient
characteristics and implant details such as implant date and
implanting center. These secondary patient identifiers were
used to create a unique, anonymized identifier for each
study patient.

Terminology (CPT) codes were extracted to identify relevant
diagnoses and procedures (Table 1).
ICD-10-PCS: International Classification of Diseases, Tenth
Revision, Procedure Coding System; ICD-10-CM: International
Classification of Diseases, Tenth Revision, Clinical Modification;
CPT: Current Procedural Terminology; IPG: implantable pulse
generator; MER: microelectrode recording.
The CMS Master Beneficiary Summary File (MBSF)
provided unique patient characteristics of age, sex,
geographical location, race or ethnicity, and date of death.
Each patient was assigned a unique, anonymized identifier
that allowed longitudinal tracking of healthcare encounters
via CMS claims files on the Virtual Research Data Center
(VRDC) (6).

Patient Selection
We identified patients with a Medicare claim containing
a procedure code for a DBS lead implant between the
aforementioned dates. To determine if a procedure was a de
novo implant, CMS data for at least 12 months prior to the
lead implantation were analyzed to ensure the absence of any
DBS-related claims (e.g., prior DBS implant, revision/removal,
or programming/analysis). Furthermore, the subsequent DBS
IPG implantation had to occur within 3 months of the lead
implantation. DBS lead implants fulfilling both criteria were
considered an index lead implant, whereas those with insufficient
data to confirm adherence to both criteria were excluded.

Patient Device Tracking Data
The PDT database contains the device models associated
with the intracranial lead and the implantable pulse generator

Frontiers in Neurology | www.frontiersin.org
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over the enrollment period was calculated, and centers within
the top 20% were classified as High-Volume Centers. Of note,
Common Center and High-Volume Center classifications are
not mutually exclusive—a single center may fulfill criteria for
both subgroups.

This approach maximized the likelihood of including only de
novo implantations. Only patients with a primary diagnosis
of PD or ET for the index lead implant were included,
as other DBS indications were not shared among TO and
MD systems.
Longitudinal CMS data were analyzed with a minimum
follow-up of 3 months (acute period) and a maximum followup of 2 years after index lead implant, censoring for death, end of
Medicare enrollment, or end of data availability.

Outcome Measures and Statistical Analysis
The primary outcome was DBS complications necessitating
surgical revision or removal at any time during the study
period. Revisions and removals were considered collectively as
reoperations. Of note, CPT codes are different for end of service
IPG replacements and were not considered a reoperation. In
addition, the lead revision code is specific to the intracranial
portion of the implant and is not intended for revision of the
extensions or adaptors—such procedures have no specific code.
Secondary outcome measures involved analysis of lead and IPG
reoperations separately.
Diagnosis codes associated with each reoperation were used
to determine the clinical reason for reoperation (Table 1). Based
on available diagnoses, the reasons for reoperation were classified
either as infection, hardware malfunction, or other/unidentified.
Diagnoses within the other/unidentified category consisted
primarily of neurological complications and unclear diagnoses
that could not be reliably classified.
Kaplan–Meier analysis was performed to compare eventfree survival rates between MD and TO subgroups. Cumulative
hazard was determined using a Nelson–Aalen estimator.
Unadjusted survival and event rates for lead-only, IPGonly, and combined reoperations were found for the acute
period, 1-year post-index, and 2-year post-index. Survival
and cumulative event models were computed using a Cox
proportional hazard model with and without Andersen–Gill
modification; and with adjustment for implant indication, age,
sex, comorbidities, implantation year, unilateral/bilateral system,
staged lead implant, and number of IPGs implanted in the
acute period. Hazard ratios (HRs) and 95% CI were reported
for hazard differences between the two subgroups, with HR
< 1.0 indicating a lower risk in the MD subgroup. Event-free
survival and cumulative event subanalyses were performed based
on the diagnoses associated with reoperations. Subgroup analyses
using Kaplan–Meier, Anderson–Gill, univariate, and multivariate
regression models were used to determine the influence of
patient, implant, and center characteristics. With missing data,
analysis only included patients with available data and the n
involved in the subanalysis is reported.
All analyses were conducted on the CMS VRDC using the
SAS Enterprise Guide Version 7.15 HF3 (SAS Institute Inc., Cary,
NC, USA). The CMS data privacy policy requires suppression
when actual number of patients or events is fewer than 11.
In such instances, results are limited to values of “n < 11”
or the equivalent computed percentage ceiling for the cohort
of interest.

Linking Methodology to Identify Modern
Directional DBS Systems
The DBS IPG implants identified in the CMS database were
linked with implants from the PDT database using previously
described probabilistic linkage methods (7). Implanted patients
whose study identification codes matched uniquely across CMS
and PDT databases were allocated to the MD subgroup.
Approximate matches were removed from further analysis to
avoid modestly probable misclassification. All the remaining
patients were allocated to the TO subgroup.

Patient Characteristics and Covariates
The age of patient age at implant and sex were acquired from the
MBSF. Indication for implant was determined from the primary
diagnosis associated with the index lead implant claim.
Pertinent comorbidities were derived from conditions listed
in the Chronic Conditions Warehouse (CCW) section of the
MBSF and in the Elixhauser comorbidity system (8, 9). While
blinded to their prevalence in the cohort, it was determined that
atrial fibrillation, diabetes, heart failure, hypertension, stroke,
obesity, and weight loss were the most clinically relevant in DBS
surgery. Using claims data prior to the index lead implant, patient
characteristics were recorded as frequencies and percentages
for categorical variables and as means with SD for continuous
variables. Statistical differences in the patient characteristics were
tested using the t-test for continuous variables and the chi-square
test for categorical variables.
Implanted DBS systems were classified as unilateral or
bilateral based on the number of leads implanted on the day
of the index lead implant and within the acute period. CPT
modifiers for bilateral, multiple, or distinct leads were also used
to facilitate classification. Unilateral systems included patients
implanted with a single lead and those with additional leads
implanted, but later removed. Bilateral systems included patients
with multiple leads implanted without concomitant lead removal
and those with a bilateral CPT modifier associated with the IPG
implant. Bilateral systems were classified as non-staged when both
leads were implanted on the same day and staged when leads
were implanted on different days during the acute period. The
number of IPGs implanted within the acute period was recorded.
Use of microelectrode recording (MER) was recorded based on
the distinct CPT codes (Table 1).
Implanting center characteristics were derived from the CMS
database. The implanting center was determined from the
organization national provider identifier (NPI) associated with
the index lead implant. Centers with at least one implant in
both MD and TO subgroups were referred to as Common
Centers. The number of de novo implants occurring at each center
Frontiers in Neurology | www.frontiersin.org

RESULTS
Of 5,998 patients who underwent DBS lead implantation
between October 6, 2016 and December 31, 2018, 3,869
patients met inclusion and exclusion criteria (Figure 1):
4
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FIGURE 1 | CONSORT flow diagram for this study. Of 5,998 patients implanted with a DBS system between October 6, 2016 and December 31, 2018, 3,869
patients were enrolled in Medicare Parts A and B, had sufficient follow-up, and were classified as a de novo implant for Parkinson’s disease (PD) or essential tremor
(ET) and were therefore eligible for analysis.

3,256 (84.2%) in the TO subgroup and 613 (15.8%) in
the MD subgroup. This distribution of de novo system
implants is representative of practice patterns during the
aforementioned timeframe.
There was no statistical difference in baseline demographics or
in clinically relevant comorbidities between subgroups (Table 2).
As such, matching of data between subgroups was unnecessary
for statistical analysis.
Implants occurred at 283 unique centers. Mean follow-up
post-index was 626 ± 140 days, with patients in the TO subgroup
having a significantly longer follow-up duration (p < 0.001).
Full details regarding the implant characteristics are shown
in Table 3.

(45.9%) were associated with other/unclassified reasons. Of the
216 IPG reoperations, 100 (46.3%) were associated with infection,
62 (28.7%) with hardware malfunction, and 54 (25.0%) were
associated with other/unclassified reasons. Lead reoperation for
other/unclassified reasons was significantly lower in patients in
the MD subgroup (HR = 0.44, 95%CI [0.24, 0.81], p = 0.008),
but other classifications were not significantly different between
the two subgroups. Interestingly, 112 (63.6%) of the 176 lead
reoperations performed in the acute period were associated with
other/unclassified reasons, 41 (63.1%) of the 65 IPG reoperations
in the acute period were associated with infections. In the chronic
phase, the associated diagnoses were balanced across all the
three categories.

Primary Outcomes

Characteristics of Involved Centers

Of the 3,869 study patients, 379 (9.8%) required reoperation
within 2 years. Kaplan–Meier estimate of reoperations was 10.7%
for the TO subgroup and 7.8% for the MD subgroup (Table 4).
The event-free survival curves (Figure 2) show that a
significant portion of reoperations occurred within the acute
period (5.4% of patients in the TO subgroup vs. 2.3% of patients
in the MD subgroup).
After adjustment for potential confounders, patients in the
MD subgroup were 36% less likely to require reoperation (HR
= 0.64, 95%CI [0.47, 0.88], p = 0.007). This difference was more
evident for lead reoperations (HR = 0.60, 95%CI [0.42, 0.85], p =
0.005) than for IPG reoperations (HR = 0.81, 95%CI [0.52, 1.26],
p = 0.36).

Among the 283 centers, 272 (96.1%) implanted TO DBS systems
and 102 (36.0%) implanted MD DBS systems. There were 91
(32.2%) Common Centers implanting both system types, which
accounted for 1,709 (44.2%) of the entire study cohort. The
implanting center could not be determined in 339 (8.8%) patients
because there was no organization NPI associated with the
index implant. Implant procedure volume for individual centers
ranged from 1 to 122 de novo implants over the 27-month
enrollment period. About 57 centers implanting at least 21
patients with Medicare coverage were classified as High-Volume
Centers, which performed 36.0 ± 16.8 de novo implants over
the entire study period. The remaining centers performed 6.5 ±
5.4 implants.
Of 412 lead reoperations, there were 137 (33.3%) procedures
for which it could not be determined whether the reoperation
occurred at the same center as the index lead implant. Of
the remaining 275 procedures, 24 (8.7%) reoperations occurred

Reasons for Reoperation
For the 412 lead reoperations, 123 (30%) were associated with
infection, 100 (24.2%) with hardware malfunction, and 189

Frontiers in Neurology | www.frontiersin.org
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TABLE 2 | Patient demographics and selected comorbidities of clinical importance for the cohort and subgroups.

Age (years)

Total

Omnidirectional
system group

Directional
system group

n = 3,869

n = 3,256

n = 613

P-value

70.9 ± 6.9

70.9 ± 6.9

70.9 ± 7.1

0.950

Age ≥65

3,355 (86.7%)

2,829 (86.9%)

526 (85.8%)

0.471

Age ≥75

1,027 (26.5%)

867 (26.6%)

160 (26.1%)

0.786

Female sex

1,476 (38.1%)

1,242 (38.1%)

234 (38.2%)

0.990

PD

2,513 (65.0%)

2,127 (65.3%)

386 (63.0%)

ET

1,356 (35.0%)

1,129 (34.7%)

227 (37.0%)

Asian

–

35 (1.1%)

<11 (<1.8%)

Black

51 (1.3%)

36 (1.1%)

15 (2.4%)

–

46 (1.4%)

<11 (<1.8%)

Indication

0.262

Race

Hispanic
North American Native

0.181

–

<11 (<0.3%)

<11 (<1.8%)

White

3,528 (91.2%)

2,977 (91.4%)

551 (89.9%)

Other

58 (1.5%)

47 (1.4%)

11 (1.8%)

Unknown

125 (3.2%)

106 (3.3%)

19 (3.1%)

Chronic conditions warehouse comorbidities
Atrial fibrillation

282 (7.3%)

238 (7.3%)

44 (7.2%)

0.908

Diabetes

998 (25.8%)

826 (25.4%)

172 (28.1%)

0.163

Heart failure

337 (8.7%)

285 (8.8%)

52 (8.5%)

0.828

Hypertension

2,324 (60.1%)

1,948 (59.8%)

376 (61.3%)

0.484

208 (5.4%)

175 (5.4%)

33 (5.4%)

0.993

Obesity

911 (23.5%)

767 (23.6%)

144 (23.5%)

0.972

Weight loss

381 (8.2%)

257 (7.9%)

61 (10.0%)

0.089

Stroke/transient Ischemic attack
Elixhauser comorbidities

Age is represented as a mean and SD. Distributions of other demographic information are reported as the raw number of patients and the corresponding percentage of patients.
CMS data privacy policy requires suppression when actual number of patients or events is fewer than 11. In such instances, results are limited to values of “n < 11” or the equivalent
computed percentage ceiling for the cohort of interest. The p-value represents the significance of a t-test for continuous variables or the chi-square test for categorical variables between
the subgroups.

TABLE 3 | Implant characteristics for the traditional omnidirectional subgroup and the modern directional subgroup.
Traditional
omnidirectional system
group n = 3,256
Follow-up duration (days)

Modern directional
system group n = 613

P-value

<0.001

633 ± 138

585 ± 145

Bilateral lead

2,201 (67.6%)

447 (72.9%)

0.009

Implanted at common centers

1,179 (36.2%)

530 (86.5%)

<0.001

Implanted at high volume centers
(upper 20%, ≥21 implants)

1,740 (53.4%)

314 (51.2%)

0.590

Implanted with MER

2,329 (71.5%)

453 (73.9%)

0.473

MER, microelectrode recording.
Follow-up is represented as a mean and SD. Distributions of other details are reported as the raw number of patients and the corresponding percentage of patients. The p-value
represents the significance of a t-test for continuous variables or the chi-square test for categorical variables between the subgroups. Of note, Common Center and High-Volume Center
classifications are not mutually exclusive; as such, the sum of these subgroups is not expected to total to 100%.

occurred at the same center as the index lead implant. Of the
remaining 128 procedures, 17 (13.3%) reoperations occurred at
a different center.

at a different center than the index implant. Likewise, of the
216 IPG reoperations, there were 88 (40.7%) procedures for
which it could not be determined whether the reoperation

Frontiers in Neurology | www.frontiersin.org
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TABLE 4 | Rate of patients experiencing complications at selected time points, based on unadjusted Kaplan–Meier analysis (* indicates suppression of cells with fewer
than 11 counts, per Centers for Medicare and Medicaid Services policy).
Omnidirectional system group
n = 3,256
3 months

Directional system group n = 613

1 year

2 years

3 months

1 year

2 years

p-value

Lead and IPG

5.44%

8.68%

10.73%

2.28%

6.28%

7.76%

Lead only

4.79%

7.51%

9.11%

<1.8%*

4.97%

6.57%

0.033
0.031

IPG only

1.69%

3.82%

5.18%

<1.8%*

3.15%

3.96%

0.294

IPG, implantable pulse generator.
The p-value represents the significance of a t-test between the subgroups.

Influence of Covariates

patients who underwent reoperation for other/unclassified
reason, there was a 56% risk reduction in the MD
subgroup. This classification was the most common
reason for lead reoperations in the cohort. As suggested
by Rolston et al. (10), this other/unclassified reason
for reoperation is likely attributable to mispositioned
electrodes or lack of therapeutic effect, as there is no
other clear clinical indication for reoperation (10). This
interpretation supports the hypothesis that stimulation
field shaping, which has been shown to expand the
therapeutic window for stimulation (4), significantly reduces
reoperation rates.
Interestingly, we see that the primary difference between
reoperation rates occurred in the acute period. Such timing of
reoperations has been described in prior analysis of healthcare
claims data (11). With the difference between subgroups
occurring early, it is unlikely that our results are meaningfully
affected by a mean difference in follow-up of 48 days in
the setting of a mean total follow-up of 626 days. About
42.7% of all lead reoperations occurred within this acute
period, for which the majority (63.6%) may be attributable to
suboptimal electrode placement. Such a meaningful difference
in early reoperations raises the question of whether clinician
thresholds for reoperation differ between the two systems.
While nuances of clinical decision-making cannot be captured
in our analysis, the long-term follow-up data provides some
insight. After the acute period, the infection and hardware
malfunction were more common for lead reoperations and
MD systems to maintain their relative risk reduction over
time. These findings suggest MD systems have lasting safety
benefits and do not simply delay reoperations beyond the
acute period.

Age, sex, comorbidities, implant characteristics, and center
characteristics did not have statistically significant interactions
with the primary outcome of reoperations. Only implant
indication (PD vs. ET) demonstrated a significant interaction:
patients implanted for PD in the MD subgroup had fewer
reoperations (HR = 0.47, 95%CI [0.30, 0.74], p = 0.001),
whereas for patients implanted for ET, the reoperation risk was
comparable (HR = 0.96, 95%CI [0.61, 1.51], p = 0.861).
Among Common Centers, the reoperation risk remained
lower for patients in the MD subgroup (HR = 0.57, 95%CI
[0.40, 0.82], p = 0.002). This relative risk reduction was
also present in High-Volume Centers (HR = 0.56, 95%CI
[0.36, 0.88], p = 0.012), but was not statistically significant
for the remaining centers (HR = 0.79, 95%CI [0.48, 1.31],
p = 0.364). Figure 3 shows the HR of event-free survival
across subgroups.

DISCUSSION
Modern Directional DBS Systems Are
Associated With Fewer Reoperations
Using US insurance claims linked with patient device tracking
data, we found that DBS reoperations occurred 36% less
frequently within 2 years of follow-up with MD systems
than with TO systems. This reduction in cumulative hazard
over the entire study period is clinically relevant, as it
represents the overall risk to patients over long-term followup.
Separate analysis of reoperation rates for leads and IPGs
demonstrates a similar relationship for the former, but a weaker
association for the latter. As such, it appears that the primary
factor in risk reduction seen with MD systems is the difference
in lead-related complications. The unique features of stimulation
field shaping and more contemporary design and construction
with MD system leads may therefore play a significant role in
reoperation risk.

Risk Reduction Persists Across Implant
Methodologies and Center Experience
We wanted to account for the possible influence of implantation
technique on reoperations. We therefore performed a subanalysis
with Common Centers to exclude patients who might have
undergone an implant methodology not represented in both
subgroups. These centers demonstrated a similar pattern
of relative risk reduction. Furthermore, specific procedural
variables, including use of MER and number of electrodes

Suboptimal Electrode Location may Play a
Significant Role in Reoperations
Neither infection nor hardware malfunction rates were
significantly different between the two subgroups; however, for
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FIGURE 2 | Event-free survival curves for the modern directional (MD) subgroup (light blue) and the traditional omnidirectional (TO) subgroup [dark blue] with regards
to (A) lead and implantable pulse generator (IPG) reoperations combined, (B) lead only reoperations, and (C) IPG only reoperations. The number of subjects in each
subgroup at index implantation and at 3-, 6-, 12-, 18-, and 24-month follow-up are reported below each graph.
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FIGURE 3 | Subgroup analysis of hazard ratio (HR) for event-free survival from lead or implantable pulse generator reoperations. HRs are represented as squares with
95% CI bars. HRs <1 represents a reduced risk associated with modern directional systems. Columns show the number of subjects included in the subgroup
analysis is reported for each analysis; the equivalent percentage of the entire cohort that this subgroup represents is reported in parentheses. Within the subgroup
analysis, only the primary diagnosis associated with the DBS implant demonstrated a statistically significant difference (indicated by an *) with those implanted for
Parkinson’s disease experiencing a notable HR reduction compared to those implanted for essential tremor. There was no significant difference when considering age,
gender, center, center experience, use of MERs, number of electrodes implanted, or comorbidities of diabetes, hypertension, or obesity.

Given that MD systems were introduced at the beginning
of the study period, we were concerned about the possibility
that only more experienced centers would utilize newer
technology and possibly bias the results. We, therefore, used

implanted, did not significantly influence the risk reduction.
Although we were unable to control for every variable in surgical
technique, this approach broadly mitigates practice differences
across centers.
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that while the reoperation rate in the present study was 5.4% at 3
months, it increased to 9.8% by 24 months.

volume of implantation as a surrogate for experience and
performed a subanalysis based on center volume. Although
the threshold for classification as a High-Volume Center was
21 de novo implantations, it is important to recognize that
our cohort consists only of those under Medicare coverage.
As such, when considering all insurance carriers, HighVolume Centers are estimated to have performed at least
twice as many implants. Nevertheless, center volume had no
significant impact on the overall relative risk reduction. It
is, however, notable that there was a trend toward greater
risk reduction in High-Volume Centers. This finding is
particularly interesting when considering that High-Volume
Centers are also more likely to treat more complex patients.
It is possible that greater attention paid to surgical procedures
associated with a novel device could contribute to a lower
complication rate.

Limitations
While there is a wealth of data in the CMS database, we are
still limited to the information that has been captured for billing
purposes (12). As such, we could not identify complications
that did not require reoperation. Similar to other retrospective
studies, misclassifications or misdiagnoses may occur when the
most suitable procedure or diagnosis code was not submitted.
Since revision of extensions or adapters to not have a specific
code, it is possible that such procedures were coded as either
a lead revision or an IPG revision. Without the ability to
prospectively randomize patients, we were unable to control
all confounding variables. We also lacked access to richer
clinical data, which may provide a more complete picture of
the clinical scenario. As such, adjudication of specific reasons
for reoperation was not always possible. While infection and
hardware malfunction could be identified, we were unable to
classify a significant proportion of events. Since there is no
dedicated code for lack of therapeutic efficacy, it is reasonable
to interpret other/unclassified diagnoses as instances where DBS
resulted in side effects or lack of efficacy, particularly for lead
reoperations. Unfortunately, we cannot definitely consider this
etiology as the sole reason for such reoperations.
In terms of generalizability, our study only included patients
with Medicare coverage, which is only available to patients over
the age of 65. We therefore cannot extend conclusions to younger
patients or those without Medicare coverage.
While providing considerable insight into DBS reoperations,
our study also generates several questions about the reasons
underlying the observed findings.

Patients With Parkinson’s Disease
Experience Greater Risk Reduction
Patients undergoing DBS for PD demonstrated greater relative
risk reduction with MD systems than those implanted for ET.
While age and comorbidities may be different between these
cohorts, these factors did not impact reoperation rates in our
analysis. A potential reason for this difference is that the thalamic
target used for ET is more forgiving to off-target effects than
the commonly used subthalamic nucleus target used for PD.
Without DBS targets in the CMS database, we were unable to
investigate this possibility. Nevertheless, this PD-specific risk
reduction makes it less likely that differential treatment of a novel
system explains the risk reduction associated with MD systems, as
practice differences would similarly affect those with ET.

Not all Reoperations Occur at the Original
Implanting Center

CONCLUSIONS

The ability to longitudinally track patients independent of
institutional data revealed that patients may undergo reoperation
at a different center. This phenomenon is important to consider,
as it may lead to an underestimation of complication rates if
patient are lost to follow-up in single center analyses.

This is the first multicenter real-world report of device-related
complications with modern DBS systems. MD systems were
significantly less likely to require reoperation, even when
accounting for practice differences and implanting center
experience. This relative risk reduction was seen primarily in
patients with PD and was largely attributable to the reduction in
lead reoperations. This differential risk profile should be carefully
considered during device selection for patients undergoing
DBS for PD or ET. Further studies are needed to investigate
the underlying causes of DBS reoperations in order to better
understand the underpinnings of the risk reduction associated
with MD systems.

Comparison With Published DBS
Complication Rates
A recent systematic review noted that 3.8% of patients underwent
hardware removal and 4.5% underwent hardware revision (3).
The authors also presented evidence for a publication bias toward
lower complication rates. Meanwhile, healthcare claims data offer
large sample sizes free of selection bias that are representative
of different practice patterns (12). Investigation of US healthcare
claims data has revealed slightly higher complication rates with
lead and IPG revision rates within 90 days of implantation of 5.3
and 3.2%, respectively (11). Such databases also provide greater
longitudinal tracking, which has revealed that complication rates
may increase with time. Rolston et al. (10) reported reoperation
procedures represented 15.2% of all DBS surgeries in a 10year period—a statistic likely including complications in patients
implanted before the study period (10). It is therefore reasonable
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